On Thursday evening, the medtech company lowered its guidance, as the covid-19 pandemic continues to affect the number of operations being performed while also disrupting the firm's supply chain, according to an Ambu press release.
Now, Ambu expects to realize organic growth in 2021/2022 at around 17 percent compared to 17-20 percent previously forecast. It predicts that the earnings before interest an taxes will be around 10 percent, compared to 11-12 percent predicted previously.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Rumored purchase of GN Group could mean divestment of hearing aid division, says media
Inside Business has learned that a number of buyers might be looking to buy GN Store Nord stock while it’s cheap, with the plan to sell one division, GN Hearing, while keeping Audio.
EMA publishes new plan to support antibiotic development
Drug-resistant bacteria kill hundreds of thousands of people every year, and national regulatory forces across the world are now coming together to ensure a uniform approach to clinical trials for antibiotics.
IRT Manager, Clinical Drug Supply 
Clinical Trial Administrator 
Procurement Manager, Direct Materials 
Key Account Manager, Europe and Asia 
Industrial Designer- Design Engineer 
Client Talent Acquisition Specialist 
Analytical Coordinator for Analytical Development 
Project Manager & Scrum Master 
(Senior) Drug Substance Specialist 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Clinical Trial Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
2 Sales Representatives and Product Specialists 
Senior Chemical Safety Advisor 
Nordic Medical Affairs Manager 
Director Global Engineering